Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
We carried out a secondary analysis of a double-blind, placebo-controlled trial of desvenlafaxine for major depressive disorder (MDD) to explore the associations between depressive symptoms and subtypes, and functional outcomes, including work functioning. Employed outpatients with MDD were assigned randomly in a 2 : 1 ratio to receive desvenlafaxine 50 mg/day or placebo for 12 weeks. Analyses were carried out post-hoc with the intent-to-treat (ITT) sample (N=427) and a prospectively defined modified ITT sample (N=310), composed of patients with baseline 17-item Hamilton Rating Scale for Depression score of at least 20. Functional outcomes at week 12 included items and factors from the Montgomery-Åsberg Depression Rating Scale, Sheehan Disability Scale, and the Work Productivity and Activity Impairment questionnaire. In the modified ITT sample, but not in the ITT sample, desvenlafaxine-treated patients showed significantly greater improvement in several functional outcomes in the responder, nonanxious, and normal-energy patient subgroups. Improvement in the 17-item Hamilton Rating Scale for Depression total score at week 2 predicted change at week 12 in several functional outcomes. Functional improvement at 12 weeks was greater in subgroups of patients and was also significantly predicted by early improvement in depressive symptoms in employed patients with MDD treated with desvenlafaxine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Gladis, M. M., Brown, L. L., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.409 · Cited by 989 · cited 2×
“…at least 1 dose of study medication, had at least 1 postbaseline evaluation on the primary efficacy end point, and had a baseline HAM-D17 total score of at least 20, which has been used previously to identify moderately to severely depressed patients (DeRubeis et al., 2005; Dunlop and Aaron, 2010).”
MethodSocial Functioning in Depression: A Review
Hirschfeld, R. M. A., Montgomery, S. A., Keller, M. B., Kasper, S., Schatzberg, A. F., Moller, H.-J., Healy, D., Baldwin, D., Humble, M., Versiani, M., et al. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0405 · Cited by 586
How Should Remission From Depression Be Defined? The Depressed Patient’s Perspective
Zimmerman, M., McGlinchey, J. B., Posternak, M. A., Friedman, M., Attiullah, N., & Boerescu, D. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.148 · Cited by 431 · cited 6×
“Normalization of functioning is often reported by patients as more important than symptom-related outcomes and is considered by physicians as an important component of treatment response (Zimmerman et al., 2006).”
BackgroundInfluentialMcKnight, P. E., & Kashdan, T. B. (2009) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.01.005 · Cited by 400 · cited 7×
“Clinical trials of antidepressant therapies should include assessments of functional impairment as an outcome measure of treatment success in patients with MDD (Bech, 2005; McKnight and Kashdan, 2009; Greer et al., 2010; Langlieb and Guico-Pabia, 2010; Lam et al., 2011).”
BackgroundInfluentialHealth and disability costs of depressive illness in a major U.S. corporation
Druss, B. G., Rosenheck, R. A., & Sledge, W. H. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.8.1274 · Cited by 395 · cited 1×
“Given that depression is estimated to be the third leading cause of disease burden in 2030, (Mathers and Loncar, 2006) it is not surprising that the economic costs associated with depression are considerably higher than that of numerous other prevalent, chronic illnesses (Druss et al., 2000).”
BackgroundSzegedi, A., Jansen, W. T., van Willigenburg, A. P. P., van der Meulen, E., Stassen, H. H., & Thase, M. E. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03780 · Cited by 341 · cited 1×
“Symptomatic improvement during the first few weeks of treatment has been shown to predict later response or remission with some antidepressants (Szegedi et al., 2003, 2009; Kok et al., 2009; Soares et al., 2014) and may also be predictive of improvements in functioning.”
Defining and Measuring Functional Recovery from Depression
Greer, T. L., Kurian, B. T., & Trivedi, M. H. (2010) · CNS Drugs · doi:10.2165/11530230-000000000-00000 · Cited by 222
Cited by
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Restoring function in major depressive disorder: A systematic review
Sheehan, D. V., Nakagome, K., Asami, Y., Pappadopulos, E. A., & Boucher, M. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.029 · Cited by 182
Self-citationGhanean, H., Ceniti, A. K., & Kennedy, S. H. (2018) · CNS Drugs · doi:10.1007/s40263-018-0490-z · Cited by 108
Oluboka, O. J., Katzman, M. A., Habert, J., McIntosh, D., MacQueen, G. M., Milev, R. V., McIntyre, R. S., & Blier, P. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx081 · Cited by 104
Florea, I., Danchenko, N., Brignone, M., Loft, H., Rive, B., & Abetz-Webb, L. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.08.008 · Cited by 35
Metadata
- Authors
- Lam, R. W., Endicott, J., Hsu, M.-A., Fayyad, R., Guico-Pabia, C., & Boucher, M.
- Venue
- International Clinical Psychopharmacology
- Published
- 2014-09
- Volume
- 29
- Issue
- 5
- Pages
- 239-251
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2315927007
- Cited by
- 28
- References
- 7
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine. https://app.cochat.ai/papers/10.1097/yic.0000000000000031
- The paper
- Lam, R. W., Endicott, J., Hsu, M.-A., Fayyad, R., Guico-Pabia, C., & Boucher, M. (2014). Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0000000000000031
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.